Production costs and potential prices for biosimilars of human insulin and insulin analogues

Abstract

IntroductionHigh prices for insulin pose a barrier to treatment for people living with diabetes, with an estimated 50% of 100 million patients needing insulin lacking reliable access. As insulin analogues replace regular human insulin (RHI) globally, their relative prices will become increasingly important. Three originator companies control 96% of the global insulin market, and few biosimilar insulins are available. We estimated the price reductions that could be achieved if numerous biosimilar manufacturers entered the insulin market.MethodsData on the price of active pharmaceutical ingredient (API) exported from India were retrieved from an online customs database. Manufacturers of insulins were contacted for price quotes. Where market API prices could not be identified, prices were estimated based on comparison of similarity, in terms of manufacturing process, with APIs for which prices were available. Potential biosimilar prices were estimated by adding costs of excipients, formulation, transport, development and regulatory costs, and a profit margin.ResultsThe manufacturing processes for RHI and insulin analogues are similar. API prices were US$24 750/kg for RHI, US$68 757/kg for insulin glargine and an estimated US$100 000/kg for other analogues. Estimated biosimilar prices were US$48–71 per patient per year for RHI, US$49–72 for neutral protamine Hagedorn (NPH) insulin and US$78–133 for analogues (except detemir: US$283–365).ConclusionTreatment with biosimilar RHI and insulin NPH could cost ≤US$72 per year and with insulin analogues ≤US$133 per year. Estimated biosimilar prices were markedly lower than the current prices for insulin analogues. Widespread availability at estimated prices may allow substantial savings globally.

Insulin prices, availability and affordability in 13 low-income and middle-income countries

“…In late 2018, Gotham and colleagues21 conservatively estimated that manufacturers’ selling prices (covering production costs, profit, transport and other costs) should be $3.29 to $4.93 for biosimilar human insulin and $5.32 to $9.13 for most analogues. Our study found governments were paying far more, particularly for analogues (but also for human insulins in some countries), showing scope for price reductions while still providing a profit for the manufacturer.…”

Why isn't the NHS making the most of biosimilar insulin?

“…Currently, three companies -Novo Nordisk, Eli Lilly and Sanofi -control 96% of the global insulin market. 5 "Some prescribers may lack confidence in biosimilar manufacturers if they do not have a track record in insulin development," says Miles Fisher, Consultant Diabetologist, Glasgow Royal Infirmary. But the growing competition may challenge the current hegemony in the insulin market.…”

New Insulins, Biosimilars, and Insulin Therapy

“…The FDA held a public hearing in May 2019 about the future of insulin biosimilars to discuss its regulatory process for biosimilar and interchangeable insulin products. We will have to see if any changes show up in the United States when this approval process for insulins will become active and what impact this will have on insulin prices (10,11).…”